USD 4.28
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| BDRX | -1.6 | -7.0 | 8.9 | -24.9 | -81.8 | -91.2 | -100.0 | -100.0 | -100.0 | -100.0 |
| S&P 500 | 1.0 | 3.7 | 2.1 | 2.3 | 8.2 | 25.4 | 31.0 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | BDRX |
| name | Biodexa Pharmaceuticals Plc |
| price | 4.28 |
| changes percentage | -1.6092 |
| change | -0.07 |
| day low | 4.28 |
| day high | 4.36 |
| year high | 74 |
| year low | 3.5 |
| market cap | 994397275 |
| price avg 50 | 4.61692 |
| price avg 200 | 14.86073 |
| exchange | NASDAQ |
| volume | 4983 |
| avg volume | 151603 |
| open | 4.36 |
| previous close | 4.35 |
| eps | -73.45 |
| pe | -0.06 |
| earnings announcement | 2025-04-25T12:00:00.000+0000 |
| shares outstanding | 580839 |
| timestamp | 2025-01-17 21:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001643918 | |||
| revenue | 381000 | 699000 | -45.49 |
| gross profit | -3686000 | -4412000 | 16.46 |
| gross profit ratio | -9.67 | -6.31 | -53.28 |
| research and development expenses | 4067000 | 5111000 | -20.43 |
| operating expenses | 4328000 | 4052000 | 6.81 |
| interest income | 83000 | 24000 | 245.83 |
| interest expense | 41000 | 53000 | -22.64 |
| ebitda | -7161000 | -7395000 | 3.16 |
| ebitdaratio | -18.8 | -12.53 | -50.06 |
| operating income | -8014000 | -8932000 | 10.28 |
| operating income ratio | -21.03 | -12.78 | -64.61 |
| net income | -7079000 | -7656000 | 7.54 |
| net income ratio | -18.58 | -10.95 | -69.64 |
| eps | -224.13 | -619.72 | 63.83 |
Revenue Growth: revenue decreased to 0 million in 2023 from 1 million in 2022 representing a change of -45.49%. This indicates a sales shrinking, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 4 million in 2023 from 5 million in 2022 representing a change of -20.43%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 4 million in 2023 from 4 million in 2022 representing a change of 6.81%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -7 million in 2023 from -7 million in 2022 representing a change of 3.16%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -8 million in 2023 from -9 million in 2022 representing a change of 10.28%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -7 million in 2023 from -8 million in 2022 representing a change of 7.54%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Gross Profit: Gross Profit increased to -4 million in 2023 from -4 million in 2022 representing a change of 16.46%. This indicates a sales profitability growth, which is a positive sign for the company.
Earnings per Share (EPS): EPS increased to -224.13 in 2023 from -224.13 in 2022 representing a change of 63.83%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q2 | 2023Q4 | Q/Q change % | |
|---|---|---|---|
| 0001643918 | |||
| revenue | 0 | 83000 | -100.00 |
| gross profit | -2189000 | -2168000 | -0.97 |
| gross profit ratio | 0 | -26.12 | 100.00 |
| research and development expenses | 2189000 | 1816000 | 20.54 |
| operating expenses | 2034000 | 1602000 | 26.97 |
| interest income | 0 | 40000 | -100.00 |
| interest expense | 0 | 0 | NaN |
| ebitda | -4155000 | -2287000 | -81.68 |
| ebitdaratio | 0 | -27.55 | 100.00 |
| operating income | -4223000 | -3770000 | -12.02 |
| operating income ratio | 0 | -45.42 | 100.00 |
| net income | -3308000 | -3511000 | 5.78 |
| net income ratio | 0 | -42.3 | 100.00 |
| eps | -10.08 | -65.94 | 84.71 |
Revenue Growth: revenue decreased to 0 million in 2024Q2 from 0 million in 2023Q4 representing a change of -100.0%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to -2 million in 2024Q2 from -2 million in 2023Q4 representing a change of -0.97%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 2 million in 2024Q2 from 2 million in 2023Q4 representing a change of 26.97%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to -3 million in 2024Q2 from -4 million in 2023Q4 representing a change of 5.78%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Research and Development (R&D) Expenses: R&D Expenses increased to 2 million in 2024Q2 from 2 million in 2023Q4 representing a change of 20.54%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -4 million in 2024Q2 from -2 million in 2023Q4 representing a change of -81.68%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -4 million in 2024Q2 from -4 million in 2023Q4 representing a change of -12.02%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -10.08 in 2024Q2 from -10.08 in 2023Q4 representing a change of 84.71%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001643918 | |||
| total assets | 10542000 | 5525000 | 90.81 |
| total liabilities | 5864000 | 2363000 | 148.16 |
| total equity | 4678000 | 3162000 | 47.94 |
| cash and cash equivalents | 5971000 | 2836000 | 110.54 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 7030000 | 4688000 | 49.96 |
| total non current assets | 3512000 | 837000 | 319.59 |
| total current liabilities | 5569000 | 1900000 | 193.11 |
| total non current liabilities | 295000 | 463000 | -36.29 |
| common stock | 1190000 | 1108000 | 7.40 |
| retained earnings | -144767000 | -135336000 | -6.97 |
| total debt | 464000 | 624000 | -25.64 |
Total Assets: Total Assets increased to 11 million in 2023 from 6 million in 2022 representing a change of 90.81%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 5 million in 2023 from 3 million in 2022 representing a change of 47.94%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 6 million in 2023 from 3 million in 2022 representing a change of 110.54%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 7 million in 2023 from 5 million in 2022 representing a change of 49.96%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 1 in 2023 from 1 in 2022 representing a change of 7.4%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 0 million in 2023 from 1 million in 2022 representing a change of -25.64%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 6 million in 2023 from 2 million in 2022 representing a change of 148.16%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 6 million in 2023 from 2 million in 2022 representing a change of 193.11%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -145 million in 2023 from -135 million in 2022 representing a change of -6.97%. This indicates an accumulated losses.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001643918 | |||
| total assets | 13968000 | 13968000 | 0.0 |
| total liabilities | 5241000 | 5241000 | 0.0 |
| total equity | 8727000 | 8727000 | 0.0 |
| cash and cash equivalents | 5055000 | 5055000 | 0.0 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 7524000 | 7524000 | 0.0 |
| total non current assets | 6444000 | 6444000 | 0.0 |
| total current liabilities | 3481000 | 3481000 | 0.0 |
| total non current liabilities | 1760000 | 1760000 | 0.0 |
| common stock | 3626000 | 3626000 | 0.0 |
| retained earnings | -147881000 | -147881000 | 0.0 |
| total debt | 382000 | 0 | NaN |
Total Debt: Total Debt increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of nan%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001643918 | |||
| net change in cash | 3135000 | -7221000 | 143.42 |
| operating cash flow | -6826000 | -7048000 | 3.15 |
| free cash flow | -7089000 | -7110000 | 0.30 |
| capital expenditure | -263000 | -62000 | -324.19 |
| depreciation and amortization | 283000 | 343000 | -17.49 |
| deferred income tax | -406000 | -832000 | 51.20 |
| stock based compensation | 28000 | 123000 | -77.24 |
| accounts payables | 0 | 0 | NaN |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -26000 | -62000 | 58.06 |
| net cash used for investing activites | -265000 | -220000 | -20.45 |
| debt repayment | -188000 | -178000 | -5.62 |
| common stock issued | 10427000 | 243000 | 4190.95 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 10226000 | 47000 | 21657.45 |
| cash at end of period | 5971000 | 2836000 | 110.54 |
| accounts receivables | 365000 | 7000 | 5114.29 |
| cash at beginning of period | 2836000 | 10057000 | -71.80 |
Net Change in Cash: Net Change in Cash increased to 3 million in 2023 from -7 million in 2022 representing a change of 143.42%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -7 million in 2023 from -7 million in 2022 representing a change of 3.15%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -7 million in 2023 from -7 million in 2022 representing a change of 0.3%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2023 from 0 million in 2022 representing a change of -324.19%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 0 million in 2023 from 0 million in 2022 representing a change of -77.24%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2023 from -1 million in 2022 representing a change of 51.2%. This indicates that the company's tax liability for future periods has increased.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from 0 million in 2022 representing a change of 5114.29%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q2 | 2023Q4 | Q/Q change % | |
|---|---|---|---|
| 0001643918 | |||
| operating cash flow | -4807000 | -2945000 | -63.23 |
| free cash flow | -4807000 | -2967000 | -62.02 |
| capital expenditure | 0 | -22000 | 100.00 |
| depreciation and amortization | 136000 | 140000 | -2.86 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 150000 | 13000 | 1053.85 |
| accounts receivables | -1298000 | 262000 | -595.42 |
| accounts payables | 0 | 0 | NaN |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | -22000 | 100.00 |
| net cash used for investing activites | -754000 | -285000 | -164.56 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 4645000 | 3974000 | 16.88 |
| net change in cash | 5055000 | 372000 | 1258.87 |
| cash at end of period | -458000 | 372000 | -223.12 |
| cash at beginning of period | 0 | 0 | NaN |
Net Change in Cash: Net Change in Cash increased to 5 million in 2024Q2 from 0 million in 2023Q4 representing a change of 1258.87%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Accounts Receivables: Accounts Receivables decreased to -1 million in 2024Q2 from 0 million in 2023Q4 representing a change of -595.42%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -5 million in 2024Q2 from -3 million in 2023Q4 representing a change of -63.23%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -5 million in 2024Q2 from -3 million in 2023Q4 representing a change of -62.02%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q2 from 0 million in 2023Q4 representing a change of 100.0%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 0 million in 2024Q2 from 0 million in 2023Q4 representing a change of 1053.85%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q2 2021 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 12.06 | 56.58 | -78.68 |
| net income per share | -224.13 | -619.72 | 63.83 |
| operating cash flow per share | -216.12 | -570.5 | 62.12 |
| free cash flow per share | -224.44 | -575.52 | 61.00 |
| cash per share | 189.05 | 229.56 | -17.65 |
| book value per share | 148.11 | 255.95 | -42.13 |
| tangible book value per share | 54.99 | 255.46 | -78.47 |
| shareholders equity per share | 148.11 | 255.95 | -42.13 |
| interest debt per share | 15.99 | 54.8 | -70.82 |
| market cap | 1663964.13 | 80477874.69 | -97.93 |
| enterprise value | -3843035.87 | 78265874.69 | -104.91 |
| pe ratio | -0.24 | -10.51 | 97.76 |
| price to sales ratio | 4.37 | 115.13 | -96.21 |
| pocfratio | -0.24 | -11.42 | 97.87 |
| pfcf ratio | -0.23 | -11.32 | 97.93 |
| pb ratio | 0.36 | 25.45 | -98.60 |
| ptb ratio | 0.36 | 25.45 | -98.60 |
| ev to sales | -10.09 | 111.97 | -109.01 |
| enterprise value over ebitda | 0.54 | -10.58 | 105.07 |
| ev to operating cash flow | 0.56 | -11.1 | 105.07 |
| ev to free cash flow | 0.54 | -11.01 | 104.92 |
| earnings yield | -4.25 | -0.1 | -4372.01 |
| free cash flow yield | -4.26 | -0.09 | -4722.23 |
| debt to equity | 0.1 | 0.2 | -49.74 |
| debt to assets | 0.04 | 0.11 | -61.03 |
| net debt to ebitda | 0.77 | 0.3 | 157.10 |
| current ratio | 1.26 | 2.47 | -48.84 |
| interest coverage | -195.46 | -168.53 | -15.98 |
| income quality | 0.96 | 0.92 | 4.74 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 11.4 | 6.5 | 75.39 |
| research and ddevelopement to revenue | 10.67 | 7.31 | 45.99 |
| intangibles to total assets | 0.28 | 0.0 | 25589.35 |
| capex to operating cash flow | -0.04 | -0.01 | -337.99 |
| capex to revenue | 0.69 | 0.09 | 678.24 |
| capex to depreciation | 0.93 | 0.18 | 414.13 |
| stock based compensation to revenue | 0.07 | 0.18 | -58.24 |
| graham number | 864.22 | 1889.15 | -54.25 |
| roic | -1.47 | -2.59 | 43.10 |
| return on tangible assets | -0.93 | -1.39 | 32.86 |
| graham net net | 8.96 | 58.26 | -84.62 |
| working capital | 1461000 | 2788000 | -47.60 |
| tangible asset value | 1737000 | 3156000 | -44.96 |
| net current asset value | 1166000 | 2325000 | -49.85 |
| invested capital | 4973000 | 3625000 | 37.19 |
| average receivables | 516500 | 181000 | 185.36 |
| average payables | 326500 | 412000 | -20.75 |
| average inventory | -351999.5 | 1 | -35200050.00 |
| days sales outstanding | 674.44 | 171.8 | 292.58 |
| days payables outstanding | 28.18 | 24.21 | 16.40 |
| days of inventory on hand | -63.18 | 0.0 | -88471799.04 |
| receivables turnover | 0.54 | 2.12 | -74.53 |
| payables turnover | 12.95 | 15.08 | -14.09 |
| inventory turnover | -5.78 | 5111000 | -100.00 |
| roe | -1.51 | -2.42 | 37.50 |
| capex per share | 8.33 | 5.02 | 65.92 |
ROE: Return on Equity (ROE) increased to -1.51 on 2023-12-31 from -2.42 on 2022-12-31, representing a change of 37.50%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.24 on 2023-12-31 from -10.51 on 2022-12-31, representing a change of 97.76%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.10 on 2023-12-31 from 0.20 on 2022-12-31, representing a change of -49.74%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 1.26 on 2023-12-31 from 2.47 on 2022-12-31, representing a change of -48.84%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
| 2024-06-30 Q2 | 2024-03-31 Q1 | Q/Q change % | |
|---|---|---|---|
| BDRX | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -10.08 | 0 | NaN |
| operating cash flow per share | -14.65 | 0 | NaN |
| free cash flow per share | -14.65 | 0 | NaN |
| cash per share | 15.41 | 0 | NaN |
| book value per share | 26.6 | 0 | NaN |
| tangible book value per share | 8.29 | 0 | NaN |
| shareholders equity per share | 26.6 | 0 | NaN |
| interest debt per share | 1.16 | 0 | NaN |
| market cap | 5792817.85 | 0 | NaN |
| enterprise value | 1119817.85 | -5055000 | 122.15 |
| pe ratio | -0.44 | 0 | NaN |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -1.21 | 0 | NaN |
| pfcf ratio | -1.21 | 0 | NaN |
| pb ratio | 0.66 | 0 | NaN |
| ptb ratio | 0.66 | 0 | NaN |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -0.27 | 0 | NaN |
| ev to operating cash flow | -0.23 | 0 | NaN |
| ev to free cash flow | -0.23 | 0 | NaN |
| earnings yield | -0.57 | None | NaN |
| free cash flow yield | -0.83 | 0 | NaN |
| debt to equity | 0.04 | 0 | NaN |
| debt to assets | 0.03 | 0 | NaN |
| net debt to ebitda | 1.12 | 0 | NaN |
| current ratio | 2.16 | 2.16 | 0.00 |
| interest coverage | 0 | 0 | NaN |
| income quality | 1.45 | 0 | NaN |
| dividend yield | 0 | None | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.43 | 0.43 | 0.00 |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 77.68 | 0 | NaN |
| roic | -0.41 | None | NaN |
| return on tangible assets | -0.42 | None | NaN |
| graham net net | 3.83 | 0 | NaN |
| working capital | 4043000 | 4043000 | 0.00 |
| tangible asset value | 2719000 | 2719000 | 0.00 |
| net current asset value | 2283000 | 2283000 | 0.00 |
| invested capital | 10487000 | 10487000 | 0.00 |
| average receivables | 1922000 | 961000 | 100.00 |
| average payables | 1689000 | 1001500 | 68.65 |
| average inventory | 0 | -352000 | 100.00 |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 69.44 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | None | NaN |
| payables turnover | 1.3 | None | NaN |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.38 | None | NaN |
| capex per share | 0 | 0 | NaN |
Current Ratio: Current Ratio decreased to 2.16 on 2024-06-30 Q2 from 2.16 on 2024-03-31 Q1, representing a change of 0.00%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-27 12:15:00
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-26 20:15:00
NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-22 11:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-22 08:30:00
November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces, announces that at its General Meeting held earlier today, both resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting and General Meeting can be found in the Notice of the General Meeting on the Company's website at: https://biodexapharma.com/investors/corporate-governance/#agms.
Sentiment: Negative
Publish Date: 2024-11-21 07:35:00
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications.
Sentiment: Positive
Publish Date: 2024-11-20 20:00:00
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-18 21:12:00
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ: BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-16 12:00:00
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-14 18:45:00
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-12 20:30:00
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-12 08:48:00
November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that the Company has been formally notified that the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) determined that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). As previously disclosed, the Company received notice from Nasdaq on August 27, 2024, informing the Company that it was not in compliance with the Minimum Bid Price Requirement.
Sentiment: Positive
Publish Date: 2024-11-07 16:30:00
November 7, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 22 November 2024 at 13:00 GMT was posted to shareholders yesterday. The Board of Directors is proposing two resolutions: Ordinary Resolution 1.
Sentiment: Positive
Publish Date: 2024-11-06 15:10:00
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-04 15:45:00
NEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-02 12:00:00
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ: BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-10-31 15:00:00
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Negative
Publish Date: 2024-10-30 07:25:00
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws. On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma.
Sentiment: Positive
Publish Date: 2024-10-29 16:00:00
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (“Biodexa” or “the Company”) (NASDAQ: BDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX .
Sentiment: Positive
Publish Date: 2024-10-29 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Company") (NASDAQ:BDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BDRX.
Sentiment: Negative
Publish Date: 2024-10-29 07:30:00
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws. On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
